



Breathe
Freely..
**Once
More**

VAKSIMUNE® **AI H9**

PROTECTION AGAINST
AVIAN INFLUENZA H9N2



VAKSIMUNE® AI H9

Challenges & Our Commitment:

Avian influenza virus (AIV) subtype H9N2 was first reported in 1966 and have established in multiple avian species across geographical areas including Asia, Middle East and Africa. Although AI virus subtype H9N2 is categorized as low pathogenic avian influenza (LPAI) virus, it can cause serious economic losses in poultry industry like egg drop production up to 60%. Farmers who raise poultry face many challenges due to AI H9N2, such as loss of income, difficulty in control and prevention. AI H9N2 has different lineages that are circulating in different regions of the world, such as G1-like, Y280-like, Y439-like, and F/98-like.

Our commitment is reflected in the development of VAKSIMUNE® AI H9, It offers precise antigenicity, targeted protection against current prevailing strains.

Features:

VAKSIMUNE® AI H9 is an inactivated Avian Influenza H9N2 vaccine, formulated with an oil adjuvant.

Each dose contains : **Avian Influenza H9N2 > 10^{6.5} EID₅₀**

The vaccine is characterized by an excellent quality emulsion, which not only enhances its efficacy but also ensures a high level of safety for the vaccinated birds.



Vaccination Strategy for breeder/layer:

Vaccinate on rearing period : 4-5, 10-12, 18-23 weeks

Vaccine Administration :

Vaccine can be administered via Intramuscular / subcutaneous injection

Packing size:

Available in 500 & 1000 Doses

Vaksimune® AI H9 Benefit



Prevent AI H9N2 Severe Egg Drop Production

VAKSIMUNE® AI H9 boosts chicken immune response, protecting them against egg drop production caused by avian influenza H9N2



Less Viral Shedding


VAKSIMUNE® AI H9 breaks Avian Influenza Virus transmission by reducing viral shedding and minimizing spread within and between flocks.



Antigenic Cartography

Technology to tracks and analyzes evolving H9 antigen variants, ensuring effective protection for poultry farms by staying ahead of antigenic drift.


Challenge Test on Laying Period



Resilient % Egg Production after Challenge Test

Two groups of layer chickens were compared: one vaccinated with VAKSIMUNE® AI H9, and a control group. Three weeks after the vaccination period, they were challenged with the AI H9 virus. The vaccinated group showed an initial 87% egg production, which persisted throughout the observation. The control group, initially at 86% production, experienced a continuous decline to 65-75% post-challenge, failing to recover. This aligns with findings that H9N2 AI virus decreases egg productivity, emphasizing the preventive role of vaccination.

VAKSIMUNE® AI H9 Duration of Immunity



Long Duration of Immunity

VAKSIMUNE® AI H9 proves its efficacy with HI titers of 2^{8.2} after a single chicken injection, sustaining the titers above the required standard until 11 weeks of age. A booster dose is required to maintain the desired levels. It is important to note that VAKSIMUNE® AI H9 meets the WOAHS standard, which recommends a minimum HI titer of 2³ for protection.